Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity

Bibliography

• Kaplan LM. Pharmacological therapies for obesity. Gastroenterol Clinics North Am 2010;39(1):69-79
   PubMed Web of Science ®Google Scholar
• Cannon CP, Kumar A. Treatment of overweight and obesity: lifstyle, pharmacologic and surgical options. Clin Cornerstone 2009;9(4):55-71
   PubMedGoogle Scholar
• Jones D. Novel pharmacotherapies for obesity poised to enter market. Nat Rev Drug Discov 2009;8(11):833-4
   PubMed Web of Science ®Google Scholar
• Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs 2008;13(4):383-92
   PubMedGoogle Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7(2):168-81
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10(10):767-77
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin Ther Patent 2003;13(11):1545-50
   Google Scholar
• Casini A, Antel J, Abbate F, Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841-5
   PubMed Web of Science ®Google Scholar
• De Simone G, Di Fiore A, Menchise V, Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 2005;15:2315-20
   PubMed Web of Science ®Google Scholar
• Dodgson SJ. Inhibition of mitochondrial carbonic anhydrase: a discrepancy examined. J Appl Physiol 1987;63:2134-41
   PubMed Web of Science ®Google Scholar
• Dodgson SJ, Cherian K. Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis. Am J Physiol 1989;257:E791-6
   PubMed Web of Science ®Google Scholar
• Spencer IM, Hargreaves I, Chegwidden WR. Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust. Biochem Soc Trans 1988;16:973-4
   Web of Science ®Google Scholar
• Chegwidden WR, Spencer IM. Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus. Comp Biochem Physiol 1996;115B:247-54
   Web of Science ®Google Scholar
• Lynch CJ, Fox H, Hazen SA, Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem J 1995;310:197-202
   PubMed Web of Science ®Google Scholar
• Hazen SA, Waheed A, Sly WS, Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. FASEB J 1996;10:481-90
   PubMed Web of Science ®Google Scholar
• Atwood PV. The structure and mechanism of action of pyruvate carboxylase. Int J Biochem Cell Biol 1995;27:231-49
   PubMed Web of Science ®Google Scholar
• Alldred JB, Reilly KE. Short-term regulation of acetyl CoA carboxylase in tissues of higher animals. Prog Lipid Res 1997;35:371-85
   Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23(3):146-89
   PubMedGoogle Scholar
• Vullo D, Franchi M, Gallori E, Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem 2004;47:1272-9
   PubMed Web of Science ®Google Scholar
• Nishimori I, Vullo D, Innocenti A, Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J Med Chem 2005;48:7860-6
   PubMed Web of Science ®Google Scholar
• Cecchi A, Taylor SD, Liu Y, Carbonic anhydrase inhibitors. Inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett 2005;15:5192-6
   PubMed Web of Science ®Google Scholar
• Poulsen SA, Wilkinson BL, Innocenti A, Inhibition of human mitochondrial carbonic anhydrases VA and VB with phenyl triazole benzene sulfonamides. Bioorg Med Chem Lett 2008;18:4624-7
   PubMed Web of Science ®Google Scholar
• Smaine FZ, Pacchiano F, Rami M, Carbonic anhydrase inhibitors. 2-Substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes VA and VB over the cytosolic and membrane-associated carbonic anhydrases I, II and IV. Bioorg Med Chem Lett 2008;18:6332-5
   PubMed Web of Science ®Google Scholar
• Guzel O, Innocenti A, Scozzafava A, Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl-, pyridylacetyl- and thienylacetyl- tails act as potent inhibitors of human mitochondrial isoforms VA and VB. Bioorg Med Chem 2009;17:4894-9
   PubMed Web of Science ®Google Scholar
• Davis RA, Innocenti A, Poulsen SA, Supuran CT. Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library. Bioorg Med Chem 2010;18:14-18
   PubMed Web of Science ®Google Scholar
• Maresca A, Supuran CT. (R)-/(S)-10-Camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases. Bioorg Med Chem Lett 2011;21:1334-7
   PubMed Web of Science ®Google Scholar
• Singh S, Supuran CT. QSARs on carbonic anhydrase human mitochondrial isoforms VA and VB inhibitors of some new not yet synthesized, substituted aromatic/heterocyclic sulfonamides as antiobesity agent. J Enzyme Inhib Med Chem 2012; In press
   Google Scholar
• Arechederra RL, Waheed A, Sly WS, Effect of sulfonamides as selective carbonic anhydrase Va and Vb inhibitors on mitochondrial metabolic energy conversion. ACS Med Chem Lett 2012; In press
   Google Scholar
• Picard F, Deshaies Y, Lalonde J, Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obesity Res 2000;8:656-63
   PubMedGoogle Scholar
• Gadde KM, Franciscy DM, Wagner HR II, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-5
   PubMed Web of Science ®Google Scholar
• Verrotti A, Scaparrotta A, Agostinelli S, Topiramate-induced weight loss: a review. Epilepsy Res 2011;5(5):189-99
   Google Scholar
• Allison DB, Gadde KM, Garvey WT, Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-342
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9774):1341-52
   PubMed Web of Science ®Google Scholar
• Kramer CK, Leitao CB, Pinto LC, Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev 2011;12(5):e338-47
   PubMed Web of Science ®Google Scholar
• Alterio V, Monti SM, Truppo E, The first example of significant active site reorganization in a carbonic anhydrase-inhibitor adduct: the carbonic anhydrase I–topiramate complex. Org Biomol Chem 2010;8:3528-33
   PubMed Web of Science ®Google Scholar
• Price TO, Eranki V, Banks WA, Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology 2012;153(1):362-72
   PubMed Web of Science ®Google Scholar
• Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. In: Joost HG, editor, Apetite Control. Springer Verlag, Berin, Heidelberg; 2012. p. 433-66
   Google Scholar